Found: 13
Select item for more details and to access through your institution.
Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 952, doi. 10.1002/cpdd.1464
- By:
- Publication type:
- Article
Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 974, doi. 10.1002/cpdd.1457
- By:
- Publication type:
- Article
The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1061, doi. 10.1002/cpdd.1448
- By:
- Publication type:
- Article
Safety and Pharmacokinetics of a Combined Antioxidant Therapy against Myocardial Reperfusion Injury: A Phase 1 Randomized Clinical Trial in Healthy Humans.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1051, doi. 10.1002/cpdd.1443
- By:
- Publication type:
- Article
Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1000, doi. 10.1002/cpdd.1444
- By:
- Publication type:
- Article
Clinical Implications of Co‐administering Apixaban with Key Interacting Medications.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 961, doi. 10.1002/cpdd.1446
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 947, doi. 10.1002/cpdd.1122
- Publication type:
- Article
A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1071, doi. 10.1002/cpdd.1441
- By:
- Publication type:
- Article
Comparative Bioequivalence Study of 2 Clopidogrel 75‐mg Tablet Formulations in Moroccan Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1044, doi. 10.1002/cpdd.1442
- By:
- Publication type:
- Article
Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1011, doi. 10.1002/cpdd.1436
- By:
- Publication type:
- Article
Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 985, doi. 10.1002/cpdd.1416
- By:
- Publication type:
- Article
SERENE ER Analysis Part 1‐SERENE CD: Exposure‐Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1024, doi. 10.1002/cpdd.1438
- By:
- Publication type:
- Article
SERENE ER Analysis Part 2 SERENE‐UC: Exposure‐response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1033, doi. 10.1002/cpdd.1437
- By:
- Publication type:
- Article